Your browser doesn't support javascript.
loading
Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial.
Murphy, Janet E; Wo, Jennifer Y; Ryan, David P; Clark, Jeffrey W; Jiang, Wenqing; Yeap, Beow Y; Drapek, Lorraine C; Ly, Leilana; Baglini, Christian V; Blaszkowsky, Lawrence S; Ferrone, Cristina R; Parikh, Aparna R; Weekes, Colin D; Nipp, Ryan D; Kwak, Eunice L; Allen, Jill N; Corcoran, Ryan B; Ting, David T; Faris, Jason E; Zhu, Andrew X; Goyal, Lipika; Berger, David L; Qadan, Motaz; Lillemoe, Keith D; Talele, Nilesh; Jain, Rakesh K; DeLaney, Thomas F; Duda, Dan G; Boucher, Yves; Fernández-Del Castillo, Carlos; Hong, Theodore S.
Afiliación
  • Murphy JE; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Wo JY; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Ryan DP; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Clark JW; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Jiang W; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Yeap BY; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Drapek LC; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Ly L; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Baglini CV; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Blaszkowsky LS; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Ferrone CR; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Parikh AR; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Weekes CD; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Nipp RD; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Kwak EL; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Allen JN; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Corcoran RB; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Ting DT; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Faris JE; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Zhu AX; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Goyal L; Division of Hematology/Oncology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Berger DL; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Qadan M; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Lillemoe KD; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Talele N; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Jain RK; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • DeLaney TF; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Duda DG; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Boucher Y; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Fernández-Del Castillo C; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Hong TS; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
JAMA Oncol ; 5(7): 1020-1027, 2019 Jul 01.
Article en En | MEDLINE | ID: mdl-31145418
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Losartán / Terapia Neoadyuvante / Quimioradioterapia Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Oncol Año: 2019 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pancreáticas / Protocolos de Quimioterapia Combinada Antineoplásica / Losartán / Terapia Neoadyuvante / Quimioradioterapia Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: JAMA Oncol Año: 2019 Tipo del documento: Article